Charlotte J. Imianowski, Qiang Chen, Creg J. Workman, Dario A. A. Vignali
{"title":"Regulatory T cells in the tumour microenvironment","authors":"Charlotte J. Imianowski, Qiang Chen, Creg J. Workman, Dario A. A. Vignali","doi":"10.1038/s41568-025-00832-9","DOIUrl":null,"url":null,"abstract":"<p>The powerful suppressive capabilities of regulatory T (T<sub>reg</sub>) cells and their appreciable contribution to tumour progression make them attractive immunotherapeutic targets. However, their role in systemic immune homeostasis makes it important to find ways to specifically target tumour-infiltrating T<sub>reg</sub> cells while leaving the wider system unperturbed. It is also unknown whether therapies depleting or disrupting the function of tumour-infiltrating T<sub>reg</sub> cells will provide the greatest efficacy while limiting immune-related adverse events. In addition, T<sub>reg</sub> cells share much of their biology with conventional CD4<sup>+</sup> T cells, introducing challenges when designing targeted immunotherapies. In this Review, we discuss recent advances in differentiating tumour-infiltrating T<sub>reg</sub> cells from their systemic and tissue-resident counterparts and understanding how the biology of tumour-infiltrating T<sub>reg</sub> cells differs from conventional CD4<sup>+</sup> T cells. We also discuss how recent technological advances may enable the study of tumour-infiltrating T<sub>reg</sub> cells in even greater detail, helping to identify new targets for next-generation immunotherapeutic drugs.</p>","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"4 1","pages":""},"PeriodicalIF":66.8000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41568-025-00832-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The powerful suppressive capabilities of regulatory T (Treg) cells and their appreciable contribution to tumour progression make them attractive immunotherapeutic targets. However, their role in systemic immune homeostasis makes it important to find ways to specifically target tumour-infiltrating Treg cells while leaving the wider system unperturbed. It is also unknown whether therapies depleting or disrupting the function of tumour-infiltrating Treg cells will provide the greatest efficacy while limiting immune-related adverse events. In addition, Treg cells share much of their biology with conventional CD4+ T cells, introducing challenges when designing targeted immunotherapies. In this Review, we discuss recent advances in differentiating tumour-infiltrating Treg cells from their systemic and tissue-resident counterparts and understanding how the biology of tumour-infiltrating Treg cells differs from conventional CD4+ T cells. We also discuss how recent technological advances may enable the study of tumour-infiltrating Treg cells in even greater detail, helping to identify new targets for next-generation immunotherapeutic drugs.
期刊介绍:
Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.